A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneratio
Not Applicable
- Conditions
- Exudative age-related macular degeneration
- Registration Number
- JPRN-UMIN000030010
- Lead Sponsor
- Senju Pharmaceutical Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 338
Inclusion Criteria
Not provided
Exclusion Criteria
1. Presence of subfoveal subretinal haemorrhage 2. Presence of subfoveal fibrosis or atrophic 3. Presence of retinal pigment epithelial tear 4. Presence of choroidal neovascularization associated with any other disease 5. Presence of any other retinochoroidal disease that would affect the assessment of visual acuity 6. Presence of vitreous haemorrhage 7. Prior treatment with any anti-VEGF agents 8. History of surgical intervention for age-related macular degeneration 9. History of allergy or significant adverse drug reaction to any ingredients of drugs used in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in best-corrected visual acuity
- Secondary Outcome Measures
Name Time Method